MCK supply chain intelligence for McKesson Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
McKesson sits inside pharmaceutical distribution, healthcare logistics, specialty drug, medical supply, and retail pharmacy networks. ChainSifter tracks verified McKesson supplier and customer relationships.
Use this MCK supply chain page to review healthcare distribution relationships, source evidence, and related supplier or customer chain pages.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CHRS | Coherus Oncology, Inc. | 95% | Reciprocal relationship from CHRS graph: revenue was generated in the United States. The Company’s net revenue was as follows: Year Ended December 31, (in thousands) … |
| ADCT | ADC Therapeutics SA | 92% | Reciprocal relationship from ADCT graph: Customers from which we derive more than 10% of our total product revenues for the three months ended March 31, 2026 and 2025 are as follows: Three Months End… |
| JAZZ | Jazz Pharmaceuticals plc | 92% | Reciprocal relationship from JAZZ graph: Reciprocal relationship from MCK graph: Reciprocal relationship from JAZZ graph: The following table presents a summary of the percentage of total revenues fr… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 90% | Reciprocal relationship from AMPH graph: al. ANP currently manufactures heparin sodium for our enoxaparin product, isoproterenol, hyaluronidase, and medroxyprogesterone for Amphastar’s current produc… |
| GILD | Gilead Sciences, Inc. | 85% | Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced b… |
| MGNX | MacroGenics, Inc. | 85% | Reciprocal relationship from MGNX graph: Reciprocal relationship from MCK graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from MCK graph: Reciprocal relationship from MGNX gra… |
| RIGL | Rigel Pharmaceuticals, Inc. | 85% | Reciprocal relationship from RIGL graph: onouncements For a discussion of recent accounting pronouncements, see “Note 1– Description of Business and Summary of Significant Accounting Policies”, in th… |
| SCLX | Scilex Holding Company | 85% | Reciprocal relationship from SCLX graph: 5, LLC (“Cardinal Health 105”), ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to re… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CAH graph: Reciprocal relationship from MCK graph: nternational, national, regional, and l… |
| CAH | Cardinal Health, Inc. | 72% | nternational, national, regional, and local full-line, short-line, and specialty distributors, service merchandisers, self-warehousing chain drug stores, manufacturers engaged in direct distribution,… |
| COR | Cencora, Inc. | 72% | Reciprocal relationship from COR graph: Reciprocal relationship from MCK graph: Reciprocal relationship from COR graph: sed to manage the majority of its transactional volume. The warehouse operating… |
| CTOR | Citius Oncology, Inc. | 72% | Reciprocal relationship from CTOR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers a… |
| CTXR | Citius Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CTXR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers a… |
| CVS | CVS Health Corporation | 72% | Reciprocal relationship from CVS graph: Reciprocal relationship from MCK graph: venues and approximately % of total trade accounts receivable at March 31, 2025. Sales to the Company’s largest custome… |
| CVS | CVS Health Corporation | 72% | venues and approximately % of total trade accounts receivable at March 31, 2025. Sales to the Company’s largest customer, CVS Health Corporation (“CVS”), accounted for approximately % of its total co… |
| EMMA | Emmaus Life Sciences, Inc. | 72% | Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, Endari® was marketed and sold in the U.S.… |
| HALO | Halozyme Therapeutics, Inc. | 72% | Reciprocal relationship from HALO graph: Contents Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information… |
| HROW | Harrow, Inc. | 72% | Reciprocal relationship from HROW graph: uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the ava… |
| HSIC | Henry Schein, Inc. | 72% | Reciprocal relationship from HSIC graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HSIC graph: s, as well as several manufacturers, of dental and medical products, primaril… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: ng at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain websites and other media channels (e.g., … |
| LOW | Lowe's Companies, Inc. | 72% | Reciprocal relationship from LOW graph: e Home Depot, Inc. (a home improvement retailer), 2010 – 2012; Vice President, Merchandising, The Home Depot, Inc., 2006 – 2010. Janice M. Dupré 60 Executive V… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: . Includes cumulative translation adjustments. Amount in 2025 includes the reversal of $ million for a Zerbaxa (ceftolozane and tazobactam) sales-based milesto… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from REGN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from REGN gra… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from SUPN graph: could be harmed. The majority of our product sales are to pharmaceutical whol… |
| TEVA | Teva Pharmaceutical Industries Limited | 72% | Reciprocal relationship from TEVA graph: Reciprocal relationship from MCK graph: Reciprocal relationship from TEVA graph: 80 AJOVY 84 63 42 COPAXONE 48 63 64 AUSTEDO 46 15 8 Other* 349 278 257 Total … |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | Reciprocal relationship from VRTX graph: rty and equipment, net by location are presented below. F-47 VERTEX PHARMACEUTICALS INCORPORATED Notes to Consolidated Financial Statements (Continued) Revenu… |
| VTRS | Viatris Inc. | 72% | Reciprocal relationship from VTRS graph: Item 1A Risk Factors - “ The pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comp… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CVS | CVS Health Corporation | 95% | venues and approximately % of total trade accounts receivable at March 31, 2025. Sales to the Company’s largest customer, CVS Health Corporation (“CVS”), accounted for approximately % of its total co… |
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $11,444,651,336 across 10 awards. 36C24026K1002 EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER; 36C24026K1001 EXPRESS REPORT:… |
| CVS | CVS Health Corporation | 92% | Reciprocal relationship from CVS graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CVS graph: Reciprocal relationship from MCK graph: Sales to our largest customer, CVS Heal… |
| CVS-HEALTH-CORPORATION | CVS-HEALTH-CORPORATION | 92% | Sales to our largest customer, CVS Health Corporation ("CVS"), accounted for approximately 24% of our total consolidated revenues in fiscal 2026. |
| GROUP-PURCHASING-ORGANIZATIONS | GROUP-PURCHASING-ORGANIZATIONS | 90% | During fiscal 2026, sales to our ten largest customers, including group purchasing organizations ("GPOs") accounted for approximately 73% of our total consolidated revenues. |
| APO-PA | Apollo Global Management, Inc. | 85% | Reciprocal relationship from APO-PA graph: Reciprocal relationship from MCK graph: nnounced a definitive agreement under which funds managed by affiliates of Apollo Global Management, Inc. (“Apollo F… |
| APO-PA | Apollo Global Management, Inc. | 85% | nnounced a definitive agreement under which funds managed by affiliates of Apollo Global Management, Inc. (“Apollo Funds”) will acquire approximately 13% minority ownership interest in our Medical‑Su… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AMPH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from AMPH gra… |
| CAH | Cardinal Health, Inc. | 72% | nternational, national, regional, and local full-line, short-line, and specialty distributors, service merchandisers, self-warehousing chain drug stores, manufacturers engaged in direct distribution,… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from MCK graph: nternational, national, regional, and local full-line, short-line, and specialty distributors, service merchandisers, s… |
| COR | Cencora, Inc. | 72% | Reciprocal relationship from COR graph: Reciprocal relationship from MCK graph: Reciprocal relationship from COR graph: Reciprocal relationship from MCK graph: Reciprocal relationship from COR graph:… |
| CTOR | Citius Oncology, Inc. | 72% | Reciprocal relationship from CTOR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers a… |
| CTXR | Citius Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CTXR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers a… |
| EMMA | Emmaus Life Sciences, Inc. | 72% | Reciprocal relationship from EMMA graph: Reciprocal relationship from MCK graph: Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distri… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced b… |
| HALO | Halozyme Therapeutics, Inc. | 72% | Reciprocal relationship from HALO graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HALO graph: Contents Sales, Marketing and Distribution We have two teams of sales special… |
| HCA | HCA Healthcare, Inc. | 72% | Reciprocal relationship from HCA graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HCA graph: Reciprocal relationship from MCK graph: liabilities assumed: Current assets $ I… |
| HCA | HCA Healthcare, Inc. | 72% | liabilities assumed: Current assets $ Intangible assets Other non-current assets Current liabilities ( ) Total identifiable net assets Goodwill Net assets acquired $ SCRI Oncology, LLC On October 31,… |
| HROW | Harrow, Inc. | 72% | Reciprocal relationship from HROW graph: uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the ava… |
| HSIC | Henry Schein, Inc. | 72% | Reciprocal relationship from HSIC graph: s, as well as several manufacturers, of dental and medical products, primarily on the basis of price, breadth of product line, e-commerce capabilities, custom… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from SUPN graph: could be harmed. The majority of our product sales are to pharmaceutical whol… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MCK-DEBT | Debt stack $8.8B | 90% | Market cache reports total debt of $8.8B. |
| MCK-DEBT-7294 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2016-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MCK-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 2034 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| CAH | Cardinal Health, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| ADCT | ADC Therapeutics SA | 100.00 | 1 | ['supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 1 | ['supplier'] |
| AMPH | Amphastar Pharmaceuticals, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| SUPN | Supernus Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DEO | Diageo plc | 100.00 | 2 | |
| CLX | The Clorox Company | 100.00 | 2 | |
| CABA | Cabaletta Bio, Inc. | 100.00 | 2 | |
| CTXR | Citius Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| COR | Cencora, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DVLT | Datavault AI Inc. | 100.00 | 2 | |
| UNLYF | Unilever PLC | 100.00 | 2 |